Premium
Alkermes PLC (ALKS)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 166,69k | Automatic Disposition | 41,67 | 77,39k | -4,91% |
| 2026-06-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 111,66k | Derivative Exercise and Sale | 19,34 - 41,67 | 77,39k | - |
| 2026-05-29 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | -16,22k | 371,03k | Derivative Exercise and Sale | 19,34 - 42,36 | 7,72k | - |
| 2026-05-21 | Dr. Christopher I. WrightIndependent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 27,68k | 20,28% |
| 2026-05-21 | Dr. Christopher I. WrightIndependent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 27,68k | - |
| 2026-05-21 | Mr. Frank Anders WilsonLead Independent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 35,75k | 15,01% |
| 2026-05-21 | Mr. Frank Anders WilsonLead Independent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 35,75k | - |
| 2026-05-21 | Dr. Nancy L. SnydermanIndependent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 36,18k | 14,81% |
| 2026-05-21 | Dr. Nancy L. SnydermanIndependent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 36,18k | - |
| 2026-05-21 | Mr. Brian P. McKeonIndependent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 48,54k | 10,64% |
| 2026-05-21 | Mr. Brian P. McKeonIndependent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 48,54k | - |
| 2026-05-21 | Ms. Nancy S. LurkerIndependent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 18,22k | 34,43% |
| 2026-05-21 | Ms. Nancy S. LurkerIndependent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 18,22k | - |
| 2026-05-21 | Dr. Cato T. LaurencinIndependent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 33,77k | 16,04% |
| 2026-05-21 | Dr. Cato T. LaurencinIndependent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 33,77k | - |
| 2026-05-21 | Dr. Richard Brian GaynorIndependent Director | -1,48k | 54,50k | Derivative Exercise and Sale | 36,95 | 35,75k | - |
| 2026-05-21 | Dr. Richard Brian GaynorIndependent Director | 4,67k | 0,00 | Derivative Exercise and Retained Stock | - | 35,75k | 15,01% |
| 2026-05-21 | Mr. Shane Martin CookeIndependent Director | 2,94k | 0,00 | Derivative Exercise and Retained Stock | - | 106,68k | 2,83% |
| 2026-05-21 | Mr. Shane Martin CookeIndependent Director | -3,21k | 118,50k | Derivative Exercise and Sale | 36,95 | 106,68k | - |
| 2026-05-04 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -2,03k | 67,53k | Automatic Disposition | 33,20 | 231,56k | -0,87% |
| 2026-05-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 70,28k | Derivative Exercise and Sale | 19,34 - 33,40 | 81,39k | - |
| 2026-05-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 133,58k | Automatic Disposition | 33,40 | 81,39k | -4,68% |
| 2026-04-11 | Ms. Nancy S. LurkerIndependent Director | 2,85k | 0,00 | Derivative Exercise and Retained Stock | - | 13,56k | 26,62% |
| 2026-04-11 | Ms. Nancy S. LurkerIndependent Director | -901,00 | 30,06k | Derivative Exercise and Sale | 33,36 | 13,56k | - |
| 2026-04-06 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -2,03k | 70,32k | Automatic Disposition | 34,57 | 233,59k | -0,86% |
| 2026-04-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 80,86k | Derivative Exercise and Sale | 19,34 - 35,51 | 85,39k | - |
| 2026-04-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 142,05k | Automatic Disposition | 35,51 | 85,39k | -4,47% |
| 2026-03-02 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | -6,89k | 201,81k | Automatic Disposition | 29,29 | 7,72k | -47,17% |
| 2026-03-02 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | -6,00k | 180,00k | Automatic Disposition | 30,00 | 109,77k | -5,18% |
| 2026-03-02 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -4,07k | 120,11k | Automatic Disposition | 29,29 - 29,76 | 235,63k | -1,70% |
| 2026-03-02 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 51,90k | Derivative Exercise and Sale | 19,34 - 29,72 | 89,39k | - |
| 2026-03-02 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 118,88k | Automatic Disposition | 29,72 | 89,39k | -4,28% |
| 2026-02-26 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | 1,94k | 0,00 | Derivative Exercise and Retained Stock | - | 14,61k | 15,31% |
| 2026-02-26 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | -808,00 | 24,83k | Derivative Exercise and Sale | 30,73 | 14,61k | - |
| 2026-02-26 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | 3,01k | 0,00 | Derivative Exercise and Retained Stock | - | 115,77k | 2,67% |
| 2026-02-26 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | -2,40k | 73,84k | Derivative Exercise and Sale | 30,73 | 115,77k | - |
| 2026-02-26 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | 4,63k | 0,00 | Derivative Exercise and Retained Stock | - | 241,31k | 1,95% |
| 2026-02-26 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | -3,70k | 113,55k | Derivative Exercise and Sale | 30,73 | 241,31k | - |
| 2026-02-26 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | 3,82k | 0,00 | Derivative Exercise and Retained Stock | - | 93,39k | 4,26% |
| 2026-02-26 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -3,05k | 93,70k | Derivative Exercise and Sale | 30,73 | 93,39k | - |
| 2026-02-26 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | 3,82k | 0,00 | Derivative Exercise and Retained Stock | - | 239,69k | 1,62% |
| 2026-02-26 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -3,05k | 93,70k | Derivative Exercise and Sale | 30,73 | 239,69k | - |
| 2026-02-23 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | 1,61k | 0,00 | Derivative Exercise and Retained Stock | - | 12,67k | 14,57% |
| 2026-02-23 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | -672,00 | 21,63k | Derivative Exercise and Sale | 32,19 | 12,67k | - |
| 2026-02-23 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | 3,56k | 0,00 | Derivative Exercise and Retained Stock | - | 112,76k | 3,26% |
| 2026-02-23 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | -2,85k | 91,58k | Derivative Exercise and Sale | 32,19 | 112,76k | - |
| 2026-02-23 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | 4,86k | 0,00 | Derivative Exercise and Retained Stock | - | 236,68k | 2,10% |
| 2026-02-23 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | -3,88k | 124,90k | Derivative Exercise and Sale | 32,19 | 236,68k | - |
| 2026-02-23 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | 4,28k | 0,00 | Derivative Exercise and Retained Stock | - | 89,57k | 5,01% |
| 2026-02-23 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -3,41k | 109,90k | Derivative Exercise and Sale | 32,19 | 89,57k | - |
| 2026-02-23 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | 4,28k | 0,00 | Derivative Exercise and Retained Stock | - | 235,88k | 1,85% |
| 2026-02-23 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -3,41k | 109,90k | Derivative Exercise and Sale | 32,19 | 235,88k | - |
| 2026-02-18 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | 3,34k | 0,00 | Derivative Exercise and Retained Stock | - | 11,06k | 43,28% |
| 2026-02-18 | Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance | -1,69k | 53,93k | Derivative Exercise and Sale | 32,00 - 32,02 | 11,06k | - |
| 2026-02-18 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | 8,25k | 0,00 | Derivative Exercise and Retained Stock | - | 109,20k | 8,18% |
| 2026-02-18 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | -4,15k | 132,71k | Derivative Exercise and Sale | 32,00 - 32,02 | 109,20k | - |
| 2026-02-18 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | 9,66k | 0,00 | Derivative Exercise and Retained Stock | - | 85,30k | 12,77% |
| 2026-02-18 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -6,91k | 221,22k | Derivative Exercise and Sale | 32,00 - 32,02 | 85,30k | - |
| 2026-02-18 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | 10,27k | 0,00 | Derivative Exercise and Retained Stock | - | 231,82k | 4,64% |
| 2026-02-18 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | -7,93k | 253,71k | Derivative Exercise and Sale | 32,00 - 32,02 | 231,82k | - |
| 2026-02-18 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | 8,50k | 0,00 | Derivative Exercise and Retained Stock | - | 231,60k | 3,81% |
| 2026-02-18 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -5,53k | 177,10k | Derivative Exercise and Sale | 32,00 - 32,02 | 231,60k | - |
| 2026-02-05 | Mr. Richard F. PopsChairman & CEO | -62,23k | 2,09M | Sale to Issuer | 33,55 | 1,38M | -4,32% |
| 2026-02-05 | Mr. Blair C. JacksonExec. VP, Chief Risk Officer & COO | -8,63k | 289,40k | Sale to Issuer | 33,55 | 221,55k | -3,75% |
| 2026-02-05 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | -6,39k | 214,35k | Sale to Issuer | 33,55 | 100,95k | -5,95% |
| 2026-02-05 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -7,45k | 250,08k | Sale to Issuer | 33,55 | 75,64k | -8,97% |
| 2026-02-05 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -7,62k | 255,62k | Sale to Issuer | 33,55 | 223,11k | -3,30% |
| 2026-02-02 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 74,52k | Derivative Exercise and Sale | 19,34 - 34,24 | 57,74k | - |
| 2026-02-02 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 134,16k | Automatic Disposition | 33,54 | 57,74k | -6,48% |
| 2026-02-02 | Mr. Shane Martin CookeIndependent Director | -61,20k | 179,30k | Derivative Exercise and Sale | 31,64 - 34,78 | 103,74k | - |
| 2026-01-08 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 53,31k | Derivative Exercise and Sale | 19,34 - 30,00 | 61,74k | - |
| 2026-01-02 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 112,00k | Automatic Disposition | 28,00 | 61,74k | -6,08% |
| 2025-12-03 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -3,75k | 39,96k | Derivative Exercise and Sale | 19,34 - 30,00 | 65,74k | - |
| 2025-12-01 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 117,20k | Automatic Disposition | 29,30 | 65,74k | -5,74% |
| 2025-11-03 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 55,21k | Derivative Exercise and Sale | 19,34 - 30,38 | 69,74k | - |
| 2025-11-03 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 121,53k | Automatic Disposition | 30,38 | 69,74k | -5,42% |
| 2025-10-15 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -5,00k | 60,95k | Derivative Exercise and Sale | 19,34 - 31,53 | 73,74k | - |
| 2025-10-15 | Dr. Craig C. HopkinsonExec. VP of Research & Development and Chief Medical Officer | -4,00k | 126,12k | Automatic Disposition | 31,53 | 73,74k | -5,15% |
| 2025-08-03 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | 1,12k | 0,00 | Derivative Exercise and Retained Stock | - | 205,37k | 0,55% |
| 2025-08-03 | Mr. David Joseph GaffinExec. VP, Chief Legal Officer, CCO & Secretary | -895,00 | 23,76k | Derivative Exercise and Sale | 26,55 | 205,37k | - |
| 2025-06-09 | Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer | -6,67k | 210,14k | Automatic Disposition | 31,09 - 31,95 | 86,21k | -7,18% |
| 2025-06-08 | Dr. Christopher I. WrightIndependent Director | 2,51k | 0,00 | Derivative Exercise and Retained Stock | - | 23,01k | 12,23% |
| 2025-06-08 | Dr. Christopher I. WrightIndependent Director | -793,00 | 25,15k | Derivative Exercise and Sale | 31,71 | 23,01k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
